A Study to Assess Changes in Biomarkers Levels Following Discontinuation of Long-Term Denosumab Treatment in Postmenopausal Women
Latest Information Update: 21 Jun 2019
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics
Most Recent Events
- 21 Jun 2019 New trial record
- 15 Jun 2019 Results assessing change in biomarker levels after discontinuation of Denosumab treatment in women with postmenopausal osteoporosis presented at the 20th Annual Congress of the European League Against Rheumatism.